Heart Disease News and Research

Latest Heart Disease News and Research

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

Your skin may offer clues about how many fruits and vegetables you eat

In an exploratory study of 137 Australian adults, skin yellowness measured by reflectance spectroscopy was associated with combined fruit and vegetable intake, fruit intake alone, total carotenoid intake, body fat percentage and skin color. The findings suggest skin measurements could provide an objective dietary biomarker, but the researchers caution that skin color, ethnicity and other individual characteristics may influence how the measurements are interpreted.

30 Aug 2026

Breast cancer survivors could avoid lifelong heart medication, research suggests

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

30 Aug 2026

Remote exercise-based cardiac rehabilitation can be an additional option for heart patients

Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions as center-based programs only, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Functional angiography outperforms conventional imaging in AIR-STEMI trial

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.

29 Aug 2026

Digital registry strategy doubles heart failure treatment uptake

A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than doubled implementation of an effective type of heart failure treatment.

29 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.

29 Aug 2026

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

REACT study maps widespread silent atherosclerosis across adult lifespan

Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the REACT study presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care.

29 Aug 2026

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.

29 Aug 2026

New study detects silent atherosclerosis in healthy young adults

Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.

29 Aug 2026

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Heart Disease News and Research

Latest Heart Disease News and Research

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

Met-HeFT trial finds no cardiovascular benefit from metformin

H-ISDN shows no significant benefit in broader heart failure population

Your skin may offer clues about how many fruits and vegetables you eat

Breast cancer survivors could avoid lifelong heart medication, research suggests

Remote exercise-based cardiac rehabilitation can be an additional option for heart patients

Functional angiography outperforms conventional imaging in AIR-STEMI trial

Digital registry strategy doubles heart failure treatment uptake

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Trial shows antiplatelet therapy needs personalization after stent implantation

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

REACT study maps widespread silent atherosclerosis across adult lifespan

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

New study detects silent atherosclerosis in healthy young adults

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

Advances in cardiometabolic research and clinical trial design eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Heart Disease News and Research

Latest Heart Disease News and Research

Advances in cardiometabolic research and clinical trial design eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Newsletters you may be interested in